3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
15
Triple Negative Breast Neoplasms
9
Neoplasms
8
Prostatic Neoplasms
6
Ovarian Neoplasms
4
Neoplasm Metastasis
4
Leukemia, Myeloid, Acute
4
Fallopian Tube Neoplasms
4
Endometrial Neoplasms
4
Small Cell Lung Carcinoma
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Wilms Tumor
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Triple Negative Metastatic Breast Cancer
1
Thrombocythemia, Essential
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrence
1
Prostate Cancer Metastatic
1
Primary Myelofibrosis
1
Premenopausal HR+/HER2- Metastatic Breast Cancer
1
Polycythemia Vera
1
Pathologic Complete Response
1
Osteosarcoma
1
Neuroendocrine Tumors
1
Interventions
Oxaliplatin
32
Fluorouracil
24
Gemcitabine
23
Leucovorin
19
Docetaxel
19
pembrolizumab
17
Capecitabine
15
Radiotherapy
14
Irinotecan
13
Cisplatin
11
Bevacizumab
11
Nivolumab
8
130-nm albumin-bound paclitaxel
8
Trastuzumab
7
Erlotinib Hydrochloride
7
Cyclophosphamide
7
Albumin-Bound Paclitaxel
7
Radiosurgery
6
Paclitaxel
6
Taxes
5
S 1 (combination)
5
Metformin
5
Carboplatin
5
Blood Specimen Collection
5
Sunitinib
4
Sorafenib
4
Pemetrexed
4
Esophagectomy
4
Chemoradiotherapy
4
Cetuximab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Adenocarcinoma
×
talazoparib
×
Clear all
NCT06844383
2026-04-24
TALENT
Prostate Cancer Clinical Trials Consortium
Phase 2
Recruiting
126 enrolled